Pharmacokinetics of terbinafine in young children treated for tinea capitis

Pediatric Infectious Disease Journal

Volumn 24, Issue 10, 2005, Pages 886-891

  Abdel Rahman, Susan M ^a   Herron, Jerry ^b   Fallon Friedlander, Sheila ^c   Hauffe, Suzanne ^d   Horowitz, Anne ^d   Rivière, Gilles Jacques ^e  

^a CHILDREN S MERCY HOSPITAL   (United States)

^b Arkansas Geological Survey   (United States)

^c Pediatric and Adolescent Dermatology   (United States)

^d NOVARTIS PHARMA AG   (Switzerland)

^e NOVARTIS PHARMA K K   (Japan)

Author keywords

Antifungal; Dermatophyte; Pharmacokinetics; Terbinafine; Tinea capitis

Indexed keywords

ANTIFUNGAL AGENT; CYTOCHROME P450; CYTOCHROME P450 2C9; CYTOCHROME P450 2D6; GRISEOFULVIN; TERBINAFINE;

ADULT; AGE; ANOREXIA; AREA UNDER THE CURVE; ARTICLE; BLOOD SAMPLING; CHILD; CLINICAL ARTICLE; CLINICAL PROTOCOL; CLINICAL TRIAL; DERMATOPHYTE; DIARRHEA; DRUG ACCUMULATION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG SAFETY; EATING DISORDER; EVALUATION; FUNGUS CULTURE; GASTROINTESTINAL SYMPTOM; HEADACHE; HUMAN; LEUKOCYTE DIFFERENTIAL COUNT; MICROSPORUM; NEUTROPHIL; OPEN STUDY; OUTCOMES RESEARCH; PATIENT COMPLIANCE; PHARMACOKINETICS; PRIORITY JOURNAL; SIDE EFFECT; SINGLE DRUG DOSE; STEADY STATE; STOMACH PAIN; TINEA CAPITIS; TRICHOPHYTON;

EID: 26944488656     PISSN: 08913668     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.inf.0000180577.29853.a0     Document Type: Article

References (18)

1. Birren B. Fungal genome initiative: a white paper for fungal genomics. July 10, 2004. Available at http://www.broad.mit.edu/annotation/fungi/ fgi/July2004FGIWP.pdf.
2. Drake LA, Dinehart SM, Farmer ER, et al. Guidelines of care for superficial mycotic infections of the skin: tinea corporis, tinea cruris, tinea faciei, tinea manuum, and tinea pedis. Guidelines/Outcomes Committee American Academy of Dermatology. J Am Acad Dermatol. 1996;34:282-286.
3. Smith ES, Fleischer AB, Feldman SR. Nondermatologists are more likely than dermatologists to prescribe antifungal/corticosteroid products: an analysis of office visits for cutaneous fungal infections, 1990-1994. J Am Acad Dermatol. 1998;39:43-47.
4. Foster KW, Ghannoum MA, Elewski BE. Epidemiologic surveillance of cutaneous fungal infection in the United States from 1999 to 2002. J Am Acad Dermatol. 2004;50:748-752.
5. Gupta AK, Summerbell RC. Increased incidence of Trichophyton tonsurans tinea capitis in Ontario, Canada between 1985 and 1996. Med Mycol. 1998;36:55-60.
6. Abdel-Rahman SM, Nahata MC, Powell DA. Response to initial griseofulvin therapy in pediatric patients with tinea capitis. Ann Pharmacother. 1997;31:406-410.
7. Fleece D, Gaughan JP, Aronoff SC. Griseofijlvin versus terbinafine in the treatment of tinea capitis: a meta-analysis of randomized, clinical trials. Pediatrics. 2004;114:1312-1315.
8. Vickers AM, Sinclair JR, Zollinger M, et al. Multiple cytochrome P450s involved in the metabolism of terbinafine suggest a limited potential for drug-drug interactions. Drug Metabol Dispos. 1999;27:1029-1038.
9. Nejjam F, Zagula M, Cabiac MD, Guessous N, Humbert H, Lakhdar H. Pilot study of terbinafine in children suffering from tinea capitis: evaluation of efficacy, safety and pharmacokinetics. Br J Dermatol. 1995; 132:98-105.
10. Nedelman J, Cramer JA, Robbins B, et al. The effect of food on the pharmacokinetics of multiple-dose terbinafine in young and elderly healthy subjects. Biopharm Drug Dispos. 1997;18:127-138.
11. Boxenbaum H, Battle M. Effective half-life in clinical pharmacology. J Clin Pharmacol. 1995;35:763-766.
12. Kovarik KM, Mueller EA, Zehender H, Denouël J, Caplain H, Millerioux L. Multiple-dose pharmacokinetics and distribution in tissue of terbinafine and metabolites. Antimicrob Agents Chemother. 1995;39:2738-2741.
13. Humbert H, Denouël J, Cabiac MD, Lakhdar H, Sioufi A. Pharmacokinetics of terbinafine and five known metabolites in children, after oral administration. Biopharm Drug Dispos. 1998;19:417-423.
14. Humbert H, Cabiac MD, Denouël J, Kirkesseli S. Pharmacokinetics of terbinafine and its five main metabolites in plasma and urine, following a single oral dose in healthy subjects. Biopharm Drug Dispos. 1995;16:685-694.
15. Nedelman JR, Gibiansky E, Robbins BA, et al. Pharmacokinetics and pharmacodynamics of multiple-dose terbinafine. J Clin Pharmacol. 1996;36:452-461.
16. Devliotou-Panagiotidou D, Koussidou-Eremondi TH. Efficacy and tolerability of 8 weeks' treatment with terbinafine in children with tinea capitis caused by Microsporum canis: a comparison of three doses. J Eur Acad Dermatol Venereol. 2004;18:155-159.
17. Lipozencic J, Skerlev M, Orofino-Costa R, et al. A randomized, double-blind, parallel-group, duration-finding study of oral terbinafine and open-label, high-dose griseofulvin in children with tinea capitis due to Microsporum species. Br J Dermatol. 2002;146: 816-823.
18. Friedlander SF, Aly R, Krafchik B, et al. Terbinafine in the treatment of Trichophyton tinea capitis: a randomized, double-blind, parallel-group, duration-finding study. Pediatrics. 2002;109:602-607.